Coya Therapeutics Files Initial Ownership Statement
Ticker: COYA · Form: 3 · Filed: Apr 9, 2026 · CIK: 0001835022
| Field | Detail |
|---|---|
| Company | Coya Therapeutics, Inc. (COYA) |
| Form Type | 3 |
| Filed Date | Apr 9, 2026 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: insider-filing, ownership, disclosure
TL;DR
COYA filed initial ownership docs 4/9/26 - new big holders incoming?
AI Summary
On April 9, 2026, Coya Therapeutics, Inc. filed a Form 3, an initial statement of beneficial ownership of securities. This filing indicates the initial reporting of ownership for certain individuals or entities related to the company. The filing was accepted on the same date.
Why It Matters
This filing marks the initial disclosure of beneficial ownership of securities for Coya Therapeutics, Inc., providing transparency for investors regarding who holds significant stakes in the company.
Risk Assessment
Risk Level: low — A Form 3 filing is a standard initial disclosure and does not inherently indicate increased risk.
Key Players & Entities
- Coya Therapeutics, Inc. (company) — Issuer
- Pavao Mark H (person) — Reporting Person
- 0001835022 (company) — CIK for Coya Therapeutics, Inc.
- 0001297988 (person) — CIK for Pavao Mark H
FAQ
What type of filing is this?
This is a Form 3, an initial statement of beneficial ownership of securities.
When was the filing accepted?
The filing was accepted on April 9, 2026.
What is the CIK for Coya Therapeutics, Inc.?
The CIK for Coya Therapeutics, Inc. is 0001835022.
What is the business address of Coya Therapeutics, Inc.?
The business address is 12645 MEMORIAL DR., SUITE F1 #305 HOUSTON TX 77024.
What is the SIC code for Coya Therapeutics, Inc.?
The SIC code is 2834, Pharmaceutical Preparations.
Filing Details
This Initial Statement of Beneficial Ownership (Form 3) was filed with the SEC on April 9, 2026 by Pavao Mark H regarding Coya Therapeutics, Inc. (COYA). Form 3 filings establish the initial ownership position of company insiders when they first assume their role.